-

Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET.

A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 30 days.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.

Contacts

Investors:
Ajay Munshi
Vice President, Corporate Development
+1 781-469-1579
amunshi@verastem.com

Sherri Spear
Argot Partners
+1 212 600 1902
sherri@argotpartners.com

Media:
Lisa Buffington
Corporate Communications
+1 781-292-4205
lbuffington@verastem.com

Verastem, Inc.

NASDAQ:VSTM

Release Versions

Contacts

Investors:
Ajay Munshi
Vice President, Corporate Development
+1 781-469-1579
amunshi@verastem.com

Sherri Spear
Argot Partners
+1 212 600 1902
sherri@argotpartners.com

Media:
Lisa Buffington
Corporate Communications
+1 781-292-4205
lbuffington@verastem.com

More News From Verastem, Inc.

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

BOSTON--(BUSINESS WIRE)--Verastem doses first patient in TARGET-D 203, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated metastatic colorectal cancer...

Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investo...

Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

BOSTON--(BUSINESS WIRE)--Verastem doses first patient in TARGET-D 202, a registration-directed Phase 2 clinical trial of VS-7375 in KRAS G12D-mutated advanced NSCLC....
Back to Newsroom